- 1 Specific diagnostic method for St. Louis Encephalitis Virus using a non-structural
- 2 protein as antigen.

- 4 Simari, M.B.¹; Goñi, S.E.¹; Luppo, V.C²; Fabbri, C.M.²; Argüelles, M.H.³; Lozano,
- 5 M.E.¹; Morales, M.A.² and Iglesias, N.G.^{1*}
- 6 ¹Laboratorio de Virus Emergentes, Departamento de Ciencia y Tecnología, Universidad
- 7 Nacional de Quilmes. Bernal, Buenos Aires, Argentina. ²Departamento de Investigación,
- 8 Instituto Nacional de Enfermedades Virales Humanas "Dr. Julio Maiztegui", (INEVH-ANLIS),
- 9 Pergamino, Argentina. ³Laboratorio de Inmunología y Virología, Departamento de Ciencia y
- 10 Tecnología, Universidad Nacional de Quilmes, Bernal, Buenos Aires, Argentina.
- *Corresponding author.
- 12 gabriel.iglesias@unq.edu.ar
- 14 Abstract

13

24

- 15 St. Louis encephalitis virus (SLEV) is a mosquito-borne reemerging flavivirus in
- Argentina. It is currently necessary to develop specific serological tests that can
- efficiently discriminate the flaviviruses that circulate in our country. The immunoassays
- to diagnose SLEV lack specificity because they are based on the detection of structural
- viral proteins and the human immunoglobulins produced during infection against these
- 20 proteins cross-react with other flaviviruses. Here, we describe an enzyme-immunoassay
- designed to detect human IgG antibodies specific to the viral nonstructural protein NS5.
- The results indicate that NS5 is a promising antigen useful to discriminate SLEV from
- other circulating flaviviruses.
- 25 **Keywords:** SLEV diagnosis, *Flavivirus*, NS5.

Manuscript

27

St. Louis encephalitis virus (SLEV) is a *Flavivirus* (*Flaviviridae* family) transmitted by 28 Culex spp. mosquitoes to birds, humans and other vertebrates are incidental hosts(1). In 29 Argentina, SLEV is a re-emerging arbovirus broadly distributed with the potential to 30 give rise to epidemics of human encephalitis. The symptoms of infection in humans 31 ranged from a simple febrile headache to meningoencephalitis, and the severity of the 32 symptoms increases with the patient age (1-5). Cross-reactivity in diagnostic assays 33 between SLEV and other flaviviruses complicates differential diagnosis(6). This is 34 particularly challenging in Argentina where there are dengue virus (DENV) outbreaks 35 frequently, history of jungle yellow fever, and Zika virus (ZIKV) activity was 36 demonstrated and YFV vaccination is common in some regions (7-10). The primary 37 antigen used in assays intended for IgM and IgG detection during flavivirus infections 38 39 has been the viral envelope (E) structural protein. However, the similarity of the flavivirus E proteins causes problems with cross-reactivity and false-positive test 40 41 results, particularly in the acute and early convalescent phases. Plaque reduction neutralization testing (PRNT) is the gold standard for serological diagnosis of 42 flavivirus, but this test is expensive, labor-intensive, and requires live virus 43 manipulation. 44 Regarding the specific antiviral response pattern against SLEV, IgM antibodies 45 persistence has been detected in some patients showing that the presence of IgM might 46 not be indicative of acute infection (11, 12). Spinsanti et al. have shown that in 57% of 47 the samples studied IgM antibodies persisted after a year of the infection. However, in 48 IgM positive samples the diagnosis should be confirmed by PRNT to differentiate 49 among Flavivirus. They have also demonstrated the persistence of the four subclasses of 50 IgG antibodies for more than a year and the presence of IgG early after infection(11). 51

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

SLEV is an icosahedral single-stranded RNA virus of approximately 11 kb that encodes a single polyprotein that is processed co- and post-translationally to produce three structural proteins and seven non-structural proteins involved in virus replication(13). The non-structural protein NS5 is the viral methyl-transferase and RNA-dependent RNA polymerase(13). NS5 is an essential protein for viral RNA synthesis with a mean similarity among flaviviruses of 68%. Due to the high cross-reactivity of the E protein among flavivirus it has been proposed the use of non-structural proteins as antigens for diagnosis. It has been demonstrated that IgM and IgG antibodies against non-structural proteins NS1, NS2B, NS3, and NS5 are produced during flavivirus infections (14-20). Besides, antibodies against the nonstructural proteins NS3 and NS5 have been detected in serum samples of patients infected with WNV and DENV(15, 16, 18-20), and an NS5-based assay has been shown to discriminate between WNV and DENV or SLEV infections(19). Recently, the use of recombinant NS5 of DENV serotype 2 as antigen has allowed differentiating serum samples of patients with primary and secondary DENV infections from serum samples of patients with JEV and WNV infections taken during the acute and convalescent phases(16, 18). In this work, we developed an indirect enzyme immunoassay (EIA) using the purified full-length recombinant SLEV NS5 as antigen for the detection of IgG antibodies in human serum samples. For antigen preparation, we cloned, expressed in E. coli and purified full-length NS5 from SLEV CbaAr-4005 strain. CbaAr-4005 is a genotype III strain of SLEV isolated from Culex quinquefasciatus mosquitoes in Córdoba, Argentina, in 2005, during the largest SLEV outbreak ever reported in South America(21). After 2005 outbreak, additional SLEV outbreaks in Argentina occurred in provinces of Entre Ríos (2006), Buenos Aires (2010), and San Juan(2011) (5).

78 The NS5 expression and purification were carried out as previously described for DENV NS5 (22). Briefly, the DNA fragment containing the coding region of full-length 79 NS5 was PCR amplified and cloned into the plasmid pET-28at BamHI and XhoI sites, 80 81 adding a six-histidine tag at the amino terminus of the proteins. The protein was expressed in E. coli overnight at 20°C after induction with IPTG. The lysis of the cells 82 was carried out using a French press in phosphate binding buffer in the presence of 83 DNase I and protease inhibitor cocktail (Sigma). After centrifugation, NS5 was purified 84 on a His-Trap nickel Sepharose affinity column (GE Healthcare) using the standard 85 procedure. The protein was dialyzed against 20 mM Tris-HCl buffer, pH 7.5, 300 mM 86 NaCl, 10% glycerol, and 1 mM dithiothreitol. The dialyzed protein solution was further 87 purified by size exclusion chromatography using a Superdex 200 column. Figure 1 88 shows an SDS-PAGE of samples collected through the protein purification protocol. 89 90 Approximately 3 mg of pure SLEV NS5 protein per liter of cell culture were obtained. Anonymized barcode serum samples obtained from patients with febrile symptoms and 91 flavivirus infection confirmed or discharged at the National Reference Laboratory 92 (INEVH-ANLIS) were selected to evaluate the performance of the immunologic assay 93 described in this article. Plaque-reduction neutralization test (PRNT) was used as the 94 95 reference method for this evaluation. To perform this method, serum samples were heat inactivated at 56°C for 30 min; and two-fold serially diluted, from 1:20 to 1:2560. 96 Replicates of all dilutions of each serum sample were incubated, at 37 °C for 1 h, with 97 100 plaque-forming units (PFU) of WNV (ChimeriVax TM WNV strain), SLEV 98 (ChimeriVax TM SLEV strain), DENV-1 (Hawaii strain), DENV-2 (NGC strain), 99 DENV-3 (H87 strain), DENV-4 (H241 strain), WNV(ChimeriVax TM WNV strain), 100 101 YFV (vaccine 17D-YEL strain) and ZIKV(ARCB116141 strain). After incubation, 100 μl of each virus-serum mixture were inoculated onto a 12-well plate monolayer of Vero 102 103 C76 cells (80% confluent growth) and absorbed for 1 h at 37°C. First overlay medium

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

(containing low-melting point agarose (GIBCO BRL, Life Technologies) Hank's BSS, vitamins, amino acids, heat-inactivated calf serum, L-glutamine, and 7.5% sodium bicarbonate) was added, 0.5 mL per well and allowed to solidify for 15 minutes. The plates where SLEV and WNV were tested were incubated for four days; and plates where DENV 1-4, YFV and ZIKV were assayed were incubated for 5 days. Neutral red staining was performed by adding a neutral red second overlay (same as above without fetal calf serum and containing 4% Neutral Red [Sigma Chemical, St. Louis, MO]), 0.5 mL per well and allowed to solidify for 15 minutes. Plates were incubated overnight at 37°C with 4% CO₂ and plaques were counted and titers were calculated and expressed as the reciprocal of the serum dilution yielding a $\geq 90\%$ reduction in PFU (PRNT90). The results of the PRNT are shown in table 1. Fifty-nine sera were analyzed, 19 were positive for SLEV, 14 DENV positive (85.7% DENV- 1, 7.1 % DENV-2, 7.1 % without serotype), 9 YFV positive, 4 ZIKV positive, and 14 were negative for the analyzed viruses. Monotypic or heterotypic patterns were differentiated according to whether the serum was positive to one or several flaviviruses, respectively. In heterotypic patterns, interpretation of PRNT data was as follows: samples with a neutralizing antibody titer (PRNT90) > four-fold higher than the other flavivirus titers were considered positive for antibody to that virus. Using these samples representative of the flavivirus that cocirculate in our country we evaluated our enzyme immunoassay. We developed a standard indirect immunoassay to detect SLEV NS5-specific IgG in human sera. For this purpose, we determined an optimum NS5 concentration of 500 ng/well and a dilution 1:100 of serum samples. The antigen was coated overnight at 4°C in a 96microwell plate in a solution containing 50 mM Na₂CO₃, pH 9.6. After coating, the plates were washed three times with PBS and blocked with casein 0.2% in PBS (blocking solution) at 37°C for 1 h. Later, sera from patients were diluted 1:100 in blocking solution and incubated at 37°C for 2 h. Then, the plates were PBS washed and

incubated with HRP conjugated anti-human IgG antibody (Abcam) 1:2000 at 37°C for 130 2h. After washing the plates, ABTS (KPL labs) peroxidase substrate was added and 131 after 15 min the reaction was stopped with SDS and the optical density at 405 nm was 132 133 determined. Based on PRNT90 results we separated the samples into three groups: SLEV positive, 134 other positive flavivirus and negative samples. The results clearly show that the assay 135 efficiently discriminates SLEV positives samples from positive samples for other 136 flavivirus or negative samples (Figure 2). Figure 3 shows the results for each individual 137 138 serum sample. The cut-off to considerate a sample as positive by EIA was determined as 0.3, calculated as the mean value of negative samples plus two standard deviations. 139 Taking into account this value, 16 out of 19 samples considered positive by PRNT were 140 also positive by EIA (84%). Interestingly, the sera of SLEV infected patients (both 141 142 homotypic and heterotypic pattern) can react with the recombinant NS5 protein, and no positive sample for DENV, YFV, ZIKV or WNV resulted positive in our assay. This is 143 144 important since the presence of antibodies against NS5 in sera from patients infected with SLEV had never been reported. Using NS5 as an antigen for IgG detection we 145 were able to avoid cross-reaction with antibodies to other flaviviruses. Although the 146 147 number of serum positive samples for other flaviviruses was limited the results suggest that this test could be useful as a diagnostic method for SLEV infections. Further studies 148 with a larger panel of serum samples will be necessary to validate this method. The 149 150 three negative samples (9, 10, and 44) had low antibodies titers as judged by PRNT90. which could explain the negative result observed in our EIA. Although PRNT is the 151 gold standard method we cannot rule out that the results observed for these samples are 152 not due to cross reactivity against some other flavivirus not tested here (e.g., Ilheus 153 virus, Bussuquara virus). The specificity of NS5-based EIA might reduce or eliminate 154

the need for PRNT and therefore the requirement of BSL3 to the diagnosis of SLEV.

Also, EIA is a 1 to 2-day assay compared with PRNT that is a 5 to 7-day assay.

In Argentina different flaviviruses that can produce similar clinical symptoms cocirculate. The laboratory diagnosis is crucial to determine the etiological agent causing the disease. Molecular methods (RT-PCR) are useful during the acute-phase, and then serological methods should be used. In our assay, we were able to detect IgG antibodies against NS5 in samples collected from five to 175 days after the onset of the symptoms (Table 1 and figure 3), this includes the acute and the convalescent phase.

The complexity of flavivirus diagnosis requires developing novel diagnostic methods, that, combined with those existing, allow us properly identifying these viruses.

In conclusion, we show that the EIA test based on NS5 is a potential diagnostic method for SLEV that avoids cross-reactivity with other flaviviruses and implies a less laborious and expensive method, safer and feasible to introduce in laboratories of low complexity.

References

- 171 1. Reisen WK. Epidemiology of St. Louis encephalitis virus. Advances in virus
- research. 2003;61:139-83. Epub 2004/01/13.
- 2. Seijo A, Morales A, Poustis G, Romer Y, Efron E, Vilora G, et al. [Outbreak of
- 174 St. Louis encephalitis in the Metropolitan Buenos Aires Area]. Medicina.
- 2011;71(3):211-7. Epub 2011/07/13. Brote de encefalitis de San Luis en el area
- 176 metropolitana Buenos Aires.
- 177 3. Morales MA, Fabbri CM, Zunino GE, Kowalewski MM, Luppo VC, Enria DA,
- et al. Detection of the mosquito-borne flaviviruses, West Nile, Dengue, Saint Louis
- 179 Encephalitis, Ilheus, Bussuquara, and Yellow Fever in free-ranging black howlers
- 180 (Alouatta caraya) of Northeastern Argentina. PLoS neglected tropical diseases.
- 181 2017;11(2):e0005351. Epub 2017/02/12.
- 4. Spinsanti LI, Diaz LA, Glatstein N, Arselan S, Morales MA, Farias AA, et al.
- Human outbreak of St. Louis encephalitis detected in Argentina, 2005. Journal of
- clinical virology: the official publication of the Pan American Society for Clinical
- 185 Virology. 2008;42(1):27-33. Epub 2008/02/06.
- 186 5. Diaz A, Coffey LL, Burkett-Cadena N, Day JF. Reemergence of St. Louis
- 187 Encephalitis Virus in the Americas. Emerging infectious diseases. 2018;24(12). Epub
- 188 2018/11/21.
- Hobson-Peters J. Approaches for the development of rapid serological assays for
- surveillance and diagnosis of infections caused by zoonotic flaviviruses of the Japanese
- 191 encephalitis virus serocomplex. Journal of biomedicine & biotechnology.
- 192 2012;2012:379738. Epub 2012/05/10.
- 193 7. Morales MA, Fabbri CM. Estado actual del diagnóstico de dengue, chikungunya
- y Zika y otros arbovirus en Argentina. Actualizaciones en SIDA E INFECTOLOGÍA.
- 195 2016;24(93):111-7.
- 196 8. Artsob H, Gubler DJ, Enria DA, Morales MA, Pupo M, Bunning ML, et al. West
- Nile Virus in the New World: trends in the spread and proliferation of West Nile Virus
- in the Western Hemisphere. Zoonoses and public health. 2009;56(6-7):357-69. Epub
- 199 2009/06/03.
- 200 9. Goenaga S, Fabbri C, Duenas JC, Gardenal CN, Rossi GC, Calderon G, et al.
- 201 Isolation of yellow fever virus from mosquitoes in Misiones province, Argentina.
- 202 Vector Borne Zoonotic Dis. 2012;12(11):986-93. Epub 2012/10/03.

- 203 10. Tellechea AL, Luppo V, Morales MA, Groisman B, Baricalla A, Fabbri C, et al.
- 204 Surveillance of microcephaly and selected brain anomalies in Argentina: Relationship
- 205 with Zika virus and other congenital infections. Birth defects research.
- 206 2018;110(12):1016-26. Epub 2018/06/20.
- 207 11. Spinsanti LI, Farias AA, Aguilar JJ, del Pilar Diaz M, Contigiani MS.
- 208 Immunoglobulin G subclasses in antibody responses to St. Louis encephalitis virus
- 209 infections. Archives of virology. 2011;156(10):1861-4. Epub 2011/06/21.
- 210 12. Monath TP, Nystrom RR, Bailey RE, Calisher CH, Muth DJ. Immunoglobulin
- 211 M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis
- encephalitis. Journal of clinical microbiology. 1984;20(4):784-90. Epub 1984/10/01.
- 213 13. Lindenbach B. TH, and Rice, CM. Flaviviridae: the viruses and their replication.
- In: Fields Virology. Philadelphia: Lippincott-Raven; 2007. 1101-52 p.
- 215 14. Lorch MS, Collado MS, Arguelles MH, Rota RP, Spinsanti LI, Lozano ME, et
- al. Production of recombinant NS1 protein and its possible use in encephalitic flavivirus
- 217 differential diagnosis. Protein expression and purification. 2019;153:18-25. Epub
- 218 2018/08/21.
- 219 15. Valdes K, Alvarez M, Pupo M, Vazquez S, Rodriguez R, Guzman MG. Human
- Dengue antibodies against structural and nonstructural proteins. Clinical and diagnostic
- laboratory immunology. 2000;7(5):856-7. Epub 2000/09/06.
- 222 16. Narayan R, Raja S, Kumar S, Sambasivam M, Jagadeesan R, Arunagiri K, et al.
- 223 A novel indirect ELISA for diagnosis of dengue fever. The Indian journal of medical
- research. 2016;144(1):128-33. Epub 2016/11/12.
- 225 17. Mishra N, Caciula A, Price A, Thakkar R, Ng J, Chauhan LV, et al. Diagnosis of
- 226 Zika Virus Infection by Peptide Array and Enzyme-Linked Immunosorbent Assay.
- 227 mBio. 2018;9(2). Epub 2018/03/08.
- 228 18. Zhang T, Wang ML, Zhang GR, Liu W, Xiao XQ, Yang YS, et al. Recombinant
- 229 DENV 2 NS5: An effective antigen for diagnosis of DENV infection. Journal of
- virological methods. 2019;265:35-41. Epub 2018/12/19.
- 231 19. Wong SJ, Boyle RH, Demarest VL, Woodmansee AN, Kramer LD, Li H, et al.
- 232 Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection
- from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination.
- Journal of clinical microbiology. 2003;41(9):4217-23. Epub 2003/09/06.
- 235 20. Alvarez-Rodriguez LM, Ramos-Ligonio A, Rosales-Encina JL, Martinez-
- 236 Cazares MT, Parissi-Crivelli A, Lopez-Monteon A. Expression, purification, and
- evaluation of diagnostic potential and immunogenicity of a recombinant NS3 protein


- from all serotypes of dengue virus. Journal of tropical medicine. 2012;2012:956875.
- 239 Epub 2012/12/22.
- 240 21. Diaz LA, Nemeth NM, Bowen RA, Almiron WR, Contigiani MS. Comparison
- of argentinean saint louis encephalitis virus non-epidemic and epidemic strain infections
- 242 in an avian model. PLoS neglected tropical diseases. 2011;5(5):e1177. Epub
- 243 2011/06/02.

- 244 22. Iglesias NG, Filomatori CV, Gamarnik AV. The F1 motif of dengue virus
- polymerase NS5 is involved in promoter-dependent RNA synthesis. Journal of virology.
- 246 2011;85(12):5745-56. Epub 2011/04/08.

Table 1. PRNT₉₀ titers for 8 flaviviruses.

249

ID	D	PRNT90 Titer							7117	Result
	Days after symptoms onset	DENV 1	DENV 2	DENV 3	DENV 4	SLEV	WNV	YFV	ZIK V	Interpreta
1	6	<10	<10	<10	<10	320	10	80	<10	SLEV
2	8	<10	<10	<10	<10	320	10	80	<10	SLEV
3	13	<20	<20	<20	<20	160	<20	<20	<20	SLEV
4	25	<20	<20	<20	<20	80	<20	<20	<20	SLEV
5	12	<10	20	10	<10	40	10	<10	<10	SLEV
6	57	<10	20	10	10	>80	10	<10	<10	SLEV
7	5	<10	<10	<10	<10	40	<10	<10	<10	SLEV
8	24	<10	<10	<10	<10	160	<10	<10	<10	SLEV
9	4	<20	<20	<20	<20	20	<20	<20	<20	SLEV
10	16	<40	<40	<40	<40	40	<40	<40	<40	SLEV
11	175	<40	<40	<40	<40	80/320	<40	<40	<40	SLEV
12	5	<20	<20	<20	<20	40	<20	<20	<20	SLEV
13	62	<40	<40	<40	<40	80	<40	<40	<40	SLEV
14	30	<40	<40	<40	<40	80	<40	<40	<40	SLEV
15	70	<40	<40	<40	<40	80	<40	40	<40	SLEV
16	8	<40	<40	<40	<40	<40	<40	<40	<40	NEG
17	8	<20	<20	<20	<20	<20	<20	<20	<20	NEG
18	9	160	<20	<20	<20	<20	<20	<20	<20	DENV-
19	24	320	80	80	40	<40	<40	<40	<40	DENV-
20	13 25	<40	<40	<40	<40	<40	<40	<40	<40	NEG
21	1	<20 <20	<20 <20	<20 <20	<20 <20	<20 <20	<20 <20	<20 <20	<20 <20	NEG NEG
23	15	<20	<20	<20	<20	<20	<20	<20	<20	NEG NEG
24	7	<20	<20	<20	<20	<20	<20	<20	<20	NEG
25	20	<40	<40	<40	<40	<40	<40	<40	<40	NEG
26	NA	<20	<20	<20	<20	<20	<20	<20	<20	NEG
27	5	<20	<20	<20	<20	<20	<20	<20	40	ZIKV
28	12	<40	<40	<40	<40	<40	<40	<40	40	ZIKV
29	11	20	20	<20	<20	<20	<20	<20	<20	DENV
30	22	<40	40	<40	<40	<40	<40	<40	<40	DENV-2
31	9	<20	<20	<20	<20	<20	<20	<20	<20	NEG
32	NA	<20	<20	<20	<20	<20	<20	80	<20	YFV
33	NA	<20	<20	<20	<20	<20	<20	20	<20	YFV
34	12	80	20	20	<20	<20	<20	<20	<20	DENV-
35	19	160	<40	<40	<40	<40	<40	<40	<40	DENV-
36	17	<40	<40	<40	<40	<40	<40	320	<40	YFV
37	32	<20	<20	<20	<20	<20	<20	160	<20	YFV
38	NA	<40	<40	<40	<40	<40	<40	>1280	<40	YFV
39	8	160	<20	<20	<20	<20	<20	<20	<20	DENV-
40	19	160	40	40	<40	<40	<40	<40	<40	DENV-
41	8	320	<20	<20	<20	<20	<20	<20	<20	DENV-
42	22	>1280	40	40	<40	<40	<40	<40	<40	DENV-
43	5	<20	<20	<20	<20	20	<20	<20	<20	SLEV
44	69	<40	<40	<40	<40	40	<40	<40	<40	SLEV
45	5 NA	<20	<20	<20	<20	<20	<20	320	<20	YFV
46	NA NA	>640	20	<20	<20	<20	<20	<20	<20	DENV-
47 48	NA 10	<40 <20	<40 <20	<40 <20	<40 <20	<40 20	<40 <20	<40 <20	<40 <20	NEG SLEV
48	34	<40	<40	<40	<40	40	<40	<40	<40	SLEV
50	16	160	<20	20	<20	<20	<20	<20	<20	DENV-
51	31	160	<40	<40	<40	<40	<40	<40	<40	DENV-
52	8	<20	<20	<20	<20	<20	<20	>640	<20	YFV
53	18	<40	<40	<40	<40	<40	<40	640	<40	YFV
54	22	<20	<20	<20	<20	<20	<20	<20	<20	NEG
55	7	<40	<40	<40	<40	<40	<40	<40	<40	NEG
56	, NA	640	80	80	<40	<40	<40	<40	<40	DENV-
57	17	<40	<40	<40	<40	<40	<40	160	<40	YFV
58	NA	<40	<40	<40	<40	40	80	<40	320	ZIKV
59	NA	ND	ND	ND	ND	ND	ND	ND	ND	WNV*






Figure 1. SLEV NS5 purification. At the upper panel SLEV genome structure. Lower panel coomassie stained SDS-PAGE: T, total soluble extract injected into IMAC column. FT, flow through. W, washed fraction. E, eluted protein from IMAC. D, Superdex purified and dialyzed protein.




Figure 2. NS5 immuno-assay from serum samples. The error bars indicate the standard deviations. Statistical significance by one-way ANOVA analysis.




Figure 3. EIA NS5 IgG detection from individual samples. Results showed as mean \pm SD (*** p<0.01, ns: non-significant).

Acknowledgements

This work was funded by grants from Universidad Nacional de Quilmes and Florencio Fiorini Foundation. NGI and MEL are members of the Argentinean Council of Investigation (CONICET). MBS was granted with a CIC-BA (Commission of Scientific Investigations of Buenos Aires, Argentina) fellowship. We are grateful to Laboratorio de Arenavirus y Arbovirus, Instituto de Virología "Dr. J.M. Vanella", Facultad de Ciencias Médicas, Universidad Nacional de Córdoba (UNC), Argentina, for the genetic material of SLEV CbaAr-4005 strain.

The authors declare that there is no conflict of interest regarding the publication of this article.